Apollo Endosurgery Inc (NASDAQ:APEN) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $3.39 and traded as high as $3.26. Apollo Endosurgery shares last traded at $3.26, with a volume of 778 shares changing hands.
A number of brokerages have recently issued reports on APEN. Zacks Investment Research cut shares of Apollo Endosurgery from a “hold” rating to a “sell” rating in a report on Tuesday, September 17th. ValuEngine upgraded shares of Apollo Endosurgery from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.
The stock has a market capitalization of $67.14 million, a price-to-earnings ratio of -1.74 and a beta of 0.69. The business’s fifty day moving average price is $3.35 and its 200-day moving average price is $3.39. The company has a debt-to-equity ratio of 1.88, a current ratio of 2.24 and a quick ratio of 1.74.
Apollo Endosurgery (NASDAQ:APEN) last issued its quarterly earnings data on Tuesday, July 23rd. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). The business had revenue of $14.25 million for the quarter, compared to analyst estimates of $13.54 million. Apollo Endosurgery had a negative net margin of 69.89% and a negative return on equity of 126.08%. Equities research analysts predict that Apollo Endosurgery Inc will post -1.55 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Gagnon Securities LLC grew its holdings in shares of Apollo Endosurgery by 11.1% during the second quarter. Gagnon Securities LLC now owns 959,013 shares of the biotechnology company’s stock valued at $3,117,000 after buying an additional 95,853 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Apollo Endosurgery by 60.6% during the second quarter. Vanguard Group Inc. now owns 411,327 shares of the biotechnology company’s stock valued at $1,337,000 after purchasing an additional 155,263 shares in the last quarter. Finally, BlackRock Inc. lifted its position in shares of Apollo Endosurgery by 42.4% during the second quarter. BlackRock Inc. now owns 37,737 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 11,229 shares in the last quarter. Hedge funds and other institutional investors own 44.30% of the company’s stock.
About Apollo Endosurgery (NASDAQ:APEN)
Apollo Endosurgery, Inc, a medical technology company, focuses on the design, development, and commercialization of medical devices. Its products include OverStitch and OverStitch Sx Endoscopic Suturing System that enables advanced endoscopic procedures by allowing physicians to place full thickness sutures and secure the approximation of tissue through a flexible endoscope; Orbera365 Managed Weight Loss System; and the BIB for the treatment of overweight and obese adults.
Featured Story: Quick Ratio
Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.